Forest Labs (FRX) Offering Possible 11.11% Return Over the Next 26 Calendar Days

Forest Labs's most recent trend suggests a bullish bias. One trading opportunity on Forest Labs is a Bull Put Spread using a strike $95.00 short put and a strike $90.00 long put offers a potential 11.11% return on risk over the next 26 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $95.00 by expiration. The full premium credit of $0.50 would be kept by the premium seller. The risk of $4.50 would be incurred if the stock dropped below the $90.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Forest Labs is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Forest Labs is bullish.

The RSI indicator is at 61.65 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Forest Labs

8:31 am Forest Labs and Actavis (ACT) announce tentative election deadline of June 27, 2014
Tue, 24 Jun 2014 12:31:00 GMT

Actavis and Forest Announce Tentative Election Deadline of June 27, 2014
Tue, 24 Jun 2014 12:30:00 GMT
Business Wire – Actavis plc and Forest Laboratories, Inc. today announced that the tentative election deadline for Forest stockholders to elect the form of consideration they wish to receive in Actavis’ planned acquisition of Forest is 5:00 p.m., Eastern time, on June 27, 2014 .

Actavis and Forest Announce Tentative Election Deadline Of June 27, 2014
Tue, 24 Jun 2014 12:30:00 GMT
PR Newswire – DUBLIN and NEW YORK, June 24, 2014 /PRNewswire/ — Actavis plc (ACT) and Forest Laboratories, Inc. (FRX) today announced that the tentative election deadline for Forest stockholders to elect the form of consideration they wish to receive in Actavis' planned acquisition of Forest is 5:00 p.m., Eastern time, on June 27, 2014 (the “Election Deadline”). The Election Deadline may be extended, in which case Actavis and Forest will issue a press release announcing the new election deadline. Subject to regulatory approval and other customary closing conditions, the closing date of the acquisition is expected to be July 1, 2014. Forest stockholders who hold shares through a bank, broker, trust company or other nominee may have an earlier election deadline and should carefully review any instructions received from their bank, broker, trust company or other nominee. As previously announced, Forest stockholders can elect to receive, for each of their shares of Forest common stock, either cash, Actavis ordinary shares, or a combination of cash and Actavis ordinary shares. The cash and stock elections will be subject to proration and adjustment procedures, which are further described in the Joint Proxy Statement/Prospectus of Actavis and Forest, dated May 2, 2014. The documents necessary for Forest stockholders to make an election for their merger consideration were mailed beginning on May 30, 2014.

Forest antidepressant Viibryd succeeds in anxiety disorder trials
Mon, 23 Jun 2014 20:54:07 GMT
Reuters – Forest Laboratories Inc, which is being acquired by generic drugmaker Actavis Plc, said on Monday that its antidepressant Viibryd performed significantly better than a placebo for treating generalized anxiety disorder, according to data from three late-stage studies. Forest announced the top line results from three Phase III studies involving a total of nearly 1,500 patients suffering from generalized anxiety disorder (GAD) – two flexible-dose studies and one fixed-dose trial. In each study, the company said, Viibryd proved statistically significantly better in lowering scores on the Hamilton Rating Scale for Anxiety compared with patients who received a placebo.

Forest Laboratories, Inc. Announces Positive Topline Results from Three Phase III Trials for Vilazodone in the Treatment of Generalized Anxiety Disorder (GAD)
Mon, 23 Jun 2014 20:05:00 GMT
Business Wire – Forest Laboratories, Inc. today announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone in adult patients with generalized anxiety disorder .

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.